Ocugen, Inc. (OCGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

2.6500

-0.2000

(-7.02%)

As of 02:35PM EDT. Market open.

Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

b
Jonathan’s Audience
b
COVID-19 vaccine: Japan approves Bharat Biotech's Covaxin booster dose for travellers
Amid a major COVID surge in Japan with over 2,00,000 daily cases being reported on a daily basis recently, the island nation approved Bharat Biotech's Covaxin
v
Bharat Biotech completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no single instance of side effect or adverse reaction reported so far.
b
Anyone else read (http://traderspot.club)? Just got a tip about OCGN from them.
G
Good news tomorrow.. ocgn will go higher, alot higher
Bullish
v
Bharat Biotech expects Indian regulator's nod for intranasal Covid- vaccine
A
IMHO the ER was somewhat as expected EPS came in at ($0.09) vs expectation ($0.08), slightly off but the

Balance Sheet show great signs of improvement a sign of better things to come:
A) Working Capital up 17.3% at $112M That's Fantastic!
B) Quick Ratio now up to 12 (1=Par) That is an outstanding number for a Biotec company

I’ve been channel trading OCGN for some time now and now getting Bullish here again by building a “core position” from trading profits. Did add more pre-market … IMHO under $2.70 is a good entry point. Long and Happy Investing!
Bullish
T
$5.00 after 10;00 today
V
Bear king Jonathan look at KRTX and this is how the stock reacts to clinical success and approval’s
Bullish
B
I've lost everything
C
SG Americas Securities LLC Raises Stock Holdings in Ocugen, Inc. (NASDAQ:OCG
R
Where did Amy go ? Why is Jonathan still here?
@
Vaxart just announced a greater loss than OCGN, nevertheless their program is still behind, most of the vaccines being in animal tests phases , many of you will say what has to do with us ? well , it has , because they are at the same level, small biontech company researching new cures , vaccines, etc. ... , since they will not have any results soon many of the holders will trade hands with a stock most probable to get positive results sooner . I use to have this stock in my portfolio until early last year , sold when was 24$ despite the fact that many were saying that will go up to 70$ , never happen. I still keep on eye on it , as well as SRNE and other micro cap companies with the potential to hype on some news
Bullish
@
well , for the one that are hoping to have positive earnings good luck with that but is not going to happen, my opinion is that is holding good so far and by the end of the year we will have some gains too , patience is always rewarded
Bullish
J
One question for the board that I cannot figure out.

Why did Bharat Biotech partner with Ocugen for North American distribution of COVAXIN?

I don't see much history of Ocugen managing such a task.
From what little I have seen, it appears Bharat manages all its other global distribution itself.

Why partner with this little unknown company for such a large market?

Thanks for any informed responses
5
C'mon $3
G
Its time to buy... looks ready to launch
Bullish
M
Did Jonathan invest the car, the house, and all the spare change found in his couch into OCGN at the November highs? LOL
I cant see why he's upset always unless he did the above. GL to all!
S
"While neutralizing antibodies are key to prevent an infection, T cells are key to terminate an infection and to modulate the severity of infection," said Alessandro Sette, the study’s author and a professor at the La Jolla Institute for Immunology.
Sette said it's possible that some people's T cells clear the virus so quickly that the person never tests positive for Covid.
A
"The current suite of vaccines authorized or approved in the U.S. focus on attacking the spike protein of the coronavirus, a rather small target that is susceptible to mutations that have kept the virus circulating globally.

David Kessler, chief science officer of the White House COVID-19 Response Team and a former FDA Commissioner, said that despite the historic feat of delivering 784 million doses (of which 601 million have been administered), there is consensus in the scientific community about the next steps.

"We need vaccines with longer duration and greater breadth of protection," he said.

https://finance.yahoo.com/news/second-generation-of-covid-19-vaccines-needed-experts-201706347.html

Ooof....that is going to hit the taxpayer right where it hurts...

Billions in taxes handed over for vaccines that may have lessened the pain but lengthened the duration of the problem itself. Wait, that sounds EXACTLY what companies like Pfizer and Moderna do! Create a drug that masks or lessens symptoms WITHOUT actually curing the problem!
Bullish